Reduction of early reperfusion injury with the mitochondria-targeting peptide Bendavia

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 1, 2014, Pages 121-132

  Brown, David A ^a   Hale, Sharon L ^b   Baines, Christopher P ^c   Rio, Carlos L Del ^d   Hamlin, Robert L ^d,e   Yueyama, Yukie ^d   Kijtawornrat, Anusak ^d   Yeh, Steve T ^d   Frasier, Chad R ^a   Stewart, Luke M ^a   Moukdar, Fatiha ^a   Shaikh, Saame Raza ^a   Fisher Wellman, Kelsey H ^a   Neufer, P Darrell ^a   Kloner, Robert A ^b,f  

^a EAST CAROLINA UNIVERSITY   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d QTest Labs   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

heart; mitochondria; peptide; reactive oxygen species; reperfusion

Indexed keywords

BENDAVIA; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DRUG MECHANISM; HEART INFARCTION; HEART INFARCTION SIZE; HEART MITOCHONDRION; LIVER MITOCHONDRION; MALE; MITOCHONDRIAL PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

HEART; MITOCHONDRIA; PEPTIDE; REACTIVE OXYGEN SPECIES; REPERFUSION;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICAL SCAVENGERS; GUINEA PIGS; MALE; MICE; MITOCHONDRIA, HEART; MITOCHONDRIA, LIVER; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; OLIGOPEPTIDES; RABBITS; REACTIVE OXYGEN SPECIES; TIME FACTORS;

EID: 84890911734     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413508003     Document Type: Article

References (68)

1. Bolli R, Jeroudi MO, Patel BS, et al. Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci U S A. 1989 ; 86 (12). 4695-4699
2. Garlick PB, Davies MJ, Hearse DJ, Slater TF. Direct detection of free radicals in the reperfused rat heart using electron spin resonance spectroscopy. Circ Res. 1987 ; 61 (5). 757-760
3. Schwartz BG, Kloner RA. Coronary no reflow. J Mol Cell Cardiol. 2012 ; 52 (4). 873-882
4. Yellon DM, Dana A. The preconditioning phenomenon: a tool for the scientist or a clinical reality?. Circ Res. 2000 ; 87 (7). 543-550
5. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion - a target for cardioprotection. Cardiovasc Res. 2004 ; 61 (3). 372-385
6. Baines CP. The mitochondrial permeability transition pore and ischemia-reperfusion injury. Basic Res Cardiol. 2009 ; 104 (2). 181-188
7. Brown DA, O'Rourke B. Cardiac mitochondria and arrhythmias. Cardiovasc Res. 2010 ; 88 (2). 241-249
8. Walters AM, Porter GA, Brookes PS. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res. 2012 ; 111 (9). 1222-1236
9. Heusch G, Boengler K, Schulz R. Inhibition of mitochondrial permeability transition pore opening: the holy grail of cardioprotection. Basic Res Cardiol. 2010 ; 105 (2). 151-154
10. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008 ; 88 (2). 581-609
11. Ludman AJ, Yellon DM, Hausenloy DJ. Cardiac preconditioning for ischaemia: lost in translation. Dis Model Mech. 2010 ; 3 (1-2). 35-38
12. Downey JM, Cohen MV. Why do we still not have cardioprotective drugs?. Circ J. 2009 ; 73 (7). 1171-1177
13. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet. 2013 ; 381 (9861). 166-175
14. Kloner RA, Schwartz Longacre L. State of the science of cardioprotection: Challenges and opportunities - proceedings of the 2010 nhlbi workshop on cardioprotection. J Cardiovasc Pharmacol Ther. 2011 ; 16 (3-4). 223-232
15. Bolli R, Becker L, Gross G, Mentzer R, Balshaw D, Lathrop DA. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res. 2004 ; 95 (2). 125-134
16. Schwartz Longacre L, Kloner RA, Arai AE, et al. New horizons in cardioprotection: Recommendations from the 2010 national heart, lung, and blood institute workshop. Circulation. 2011 ; 124 (10). 1172-1179
17. Szeto HH. Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antioxid Redox Signal. 2008 ; 10 (3). 601-619
18. Kloner RA, Hale SL, Dai W. Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective peptide. J Am Heart Assoc. 2012 ; 1 (3). e001644
19. Chakrabarti AK, Feeney K, Abueg C. Rationale and design of the embrace stemi study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for st-segment elevation myocardial infarction. Am Heart J. 2013 ; 165 (4). 509-514
20. Baines CP. The mitochondrial permeability transition pore and the cardiac necrotic program. Pediatr Cardiol. 2011 ; 32 (3). 258-262
21. Baines CP. How and when do myocytes die during ischemia and reperfusion: the late phase. J Cardiovasc Pharmacol Ther. 2011 ; 16 (3-4). 239-243
22. Sloan RC, Moukdar F, Frasier CR, et al. Mitochondrial permeability transition in the diabetic heart: contributions of thiol redox state and mitochondrial calcium to augmented reperfusion injury. J Mol Cell Cardiol. 2012 ; 52 (5). 1009-1018
23. Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R. Inhibition of permeability transition pore opening by mitochondrial stat3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol. 2010 ; 105 (6). 771-785
24. Skyschally A, Schulz R, Heusch G. Cyclosporine a at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther. 2010 ; 24 (1). 85-87
25. Flaherty JT, Pitt B, Gruber JW, et al. Recombinant human superoxide dismutase (h-sod) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation. 1994 ; 89 (5). 1982-1991
26. Tsujita K, Shimomura H, Kawano H, et al. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. Am J Cardiol. 2004 ; 94 (4). 481-484
27. Leshnower BG, Kanemoto S, Matsubara M, et al. Cyclosporine preserves mitochondrial morphology after myocardial ischemia/reperfusion independent of calcineurin inhibition. Ann Thorac Surg. 2008 ; 86 (4). 1286-1292
28. Hale SL, Kloner RA. Cardioprotection with adenosine-regulating agent, gp531: Effects on no-reflow, infarct size, and blood flow following ischemia/ reperfusion in the rabbit. J Cardiovasc Pharm Ther. 2010 ; 15 (1). 60-67
29. Frasier CR, Sloan RC, Bostian PA, et al. Short-term exercise preserves myocardial glutathione and decreases arrhythmias after thiol oxidation and ischemia in isolated rat hearts. J Appl Physiol. 2011 ; 111 (6). 1751-1759
30. Brown DA, Aon MA, Frasier CR, et al. Cardiac arrhythmias induced by glutathione oxidation can be inhibited by preventing mitochondrial depolarization. J Mol Cell Cardiology. 2010 ; 48 (4). 673-679
31. Sloan RC, Rosenbaum M, O'Rourke D, et al. High doses of ketamine-xylazine anesthesia reduce cardiac ischemia-reperfusion injury in guinea pigs. J Am Assoc Lab Anim Sci. 2011 ; 50 (3). 349-354
32. McGee AM, Baines CP. Phosphate is not an absolute requirement for the inhibitory effects of cyclosporin a or cyclophilin d deletion on mitochondrial permeability transition. Biochem J. 2012 ; 443 (1). 185-191
33. Anderson EJ, Lustig ME, Boyle KE, et al. Mitochondrial h2o2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest. 2009 ; 119 (3). 573-581
34. Gibson QH, Swoboda BE, Massey V. Kinetics and mechanism of action of glucose oxidase. J Biol Chem. 1964 ; 239: 3927-3934
35. Tao Z, Raffel RA, Souid AK, Goodisman J. Kinetic studies on enzyme-catalyzed reactions: oxidation of glucose, decomposition of hydrogen peroxide and their combination. Biophys J. 2009 ; 96 (7). 2977-2988
36. Jones DP. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol. 2008 ; 295 (4). C849 - C868
37. Kelley EE, Khoo NK, Hundley NJ, Malik UZ, Freeman BA, Tarpey MM. Hydrogen peroxide is the major oxidant product of xanthine oxidase. Free Radic Biol Med. 2010 ; 48 (4). 493-498
38. Cope DK, Impastato WK, Cohen MV, Downey JM. Volatile anesthetics protect the ischemic rabbit myocardium from infarction. Anesthesiology. 1997 ; 86 (3). 699-709
39. Haessler R, Kuzume K, Chien GL, Wolff RA, Davis RF, Van Winkle DM. Anaesthetics alter the magnitude of infarct limitation by ischaemic preconditioning. Cardiovasc Res. 1994 ; 28 (10). 1574-1580
40. Walsh RS, Tsuchida A, Daly JJ, Thornton JD, Cohen MV, Downey JM. Ketamine-xylazine anaesthesia permits a katp channel antagonist to attenuate preconditioning in rabbit myocardium. Cardiovasc Res. 1994 ; 28 (9). 1337-1341
41. Miller TD, Christian TF, Hopfenspirger MR, Hodge DO, Gersh BJ, Gibbons RJ. Infarct size after acute myocardial infarction measured by quantitative tomographic 99mtc sestamibi imaging predicts subsequent mortality. Circulation. 1995 ; 92 (3). 334-341
42. Halestrap AP. What is the mitochondrial permeability transition pore?. J Mol Cell Card. 2009 ; 46 (6). 821-831
43. Halestrap AP, Pasdois P. The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta. 2009 ; 1787 (11). 1402-1415
44. Bolli R. Oxygen-derived free radicals and postischemic myocardial dysfunction ("stunned myocardium"). J Am Coll Cardiol. 1988 ; 12 (1). 239-249
45. Bognar Z, Kalai T, Palfi A, et al. A novel sod-mimetic permeability transition inhibitor agent protects ischemic heart by inhibiting both apoptotic and necrotic cell death. Free Radic Biol Med. 2006 ; 41 (5). 835-848
46. Chi LG, Tamura Y, Hoff PT, et al. Effect of superoxide dismutase on myocardial infarct size in the canine heart after 6 hours of regional ischemia and reperfusion: a demonstration of myocardial salvage. Circ Res. 1989 ; 64 (4). 665-675
47. Kilgore KS, Friedrichs GS, Johnson CR, et al. Protective effects of the sod-mimetic sc-52608 against ischemia/reperfusion damage in the rabbit isolated heart. J Mol Cell Cardiol. 1994 ; 26 (8). 995-1006
48. Abe M, Takiguchi Y, Ichimaru S, Tsuchiya K, Wada K. Comparison of the protective effect of n-acetylcysteine by different treatments on rat myocardial ischemia-reperfusion injury. J Pharmacol Sci. 2008 ; 106 (4). 571-577
49. Alberola A, Such L, Gil F, Zaragoza R, Morcillo EJ. Protective effect of n-acetylcysteine on ischaemia-induced myocardial damage in canine heart. Naunyn Schmiedebergs Arch Pharmacol. 1991 ; 343 (5). 505-510
50. Brunet J, Boily MJ, Cordeau S, Des Rosiers C. Effects of n-acetylcysteine in the rat heart reperfused after low-flow ischemia: evidence for a direct scavenging of hydroxyl radicals and a nitric oxide-dependent increase in coronary flow. Free Radic Biol Med. 1995 ; 19 (5). 627-638
51. Kingma JG, Rouleau JR. Effect of n-acetylcysteine on tissue necrosis during acute myocardial infarction in rabbits. Canad J Cardiol. 1989 ; 5 (6). 321-326
52. Sochman J, Kolc J, Vrana M, Fabian J. Cardioprotective effects of n-acetylcysteine: the reduction in the extent of infarction and occurrence of reperfusion arrhythmias in the dog. Int J Cardiol. 1990 ; 28 (2). 191-196
53. Ross MF, Kelso GF, Blaikie FH, et al. Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochemistry (Mosc). 2005 ; 70 (2). 222-230
54. Frasier CR, Moukdar F, Patel HD, et al. Redox-dependent increases in glutathione reductase and exercise preconditioning: role of nadph oxidase and mitochondria. Cardiovasc Res. 2013 ; 98 (1). 47-55
55. Szeto HH, Liu S, Soong Y, et al. Mitochondria-targeted peptide accelerates atp recovery and reduces ischemic kidney injury. J Am Soc Nephrol. 2011 ; 22 (6). 1041-1052
56. Szeto HH, Schiller PW. Novel therapies targeting inner mitochondrial membrane-from discovery to clinical development. Pharm Res. 2011 ; 28 (11). 2669-2679
57. Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004 ; 279 (33). 34682-34690
58. Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound ss-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013 ; 24 (8). 1250-1261
59. Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol. 2007 ; 292 (1). C33 - C44
60. Brown DA, Sabbah HN, Shaikh SR. Mitochondrial inner membrane lipids and proteins as targets for decreasing cardiac ischemia/reperfusion injury. Pharmacol Ther. 2013 ; 140 (3). 258-66
61. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol. 2005 ; 288 (2). H971 - H976
62. Kin H, Zhao ZQ, Sun HY, et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res. 2004 ; 62 (1). 74-85
63. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008 ; 359 (5). 473-481
64. Matsumoto-Ida M, Akao M, Takeda T, Kato M, Kita T. Real-time 2-photon imaging of mitochondrial function in perfused rat hearts subjected to ischemia/reperfusion. Circulation. 2006 ; 114 (14). 1497-1503
65. Slodzinski MK, Aon MA, O'Rourke B. Glutathione oxidation as a trigger of mitochondrial depolarization and oscillation in intact hearts. J Mol Cell Cardiol. 2008 ; 45 (5). 650-660
66. Yang XM, Liu Y, Cui L, et al. Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovasc Drugs Ther. 2013 ; 27 (2). 109-115
67. Dai DF, Chen T, Szeto H, et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol. 2011 ; 58 (1). 73-82
68. Sabbah HN, Gupta RC, Szekely K, Wang M, Zhang K, Rstogi S. Bendavia (mtp-131), a novel mitochondria-targeting peptide, improves activity and expression of cytochrome c oxidase and attenuates mediators of cardiomyocyte apoptosis in left ventricular myocardium of dogs with advanced heart failure. J Am Coll Cardiol. 2013 ; 61 (10). E710